• In April 2026, Biogen Inc. reported first-quarter 2026 results showing revenue of US$2.48 billion and net income of US$319.5 million, with earnings per share rising versus the prior year but accompanied by lower full-year guidance due to higher research and development spending and expected pressure on older multiple sclerosis drugs.
• Biogen also agreed to acquire TJ Biopharma’s Greater China rights to felzartamab for up to US$850 million, consolidating worldwide control of this late-stage immunology asset while increasing near-term expenses through an Acquired In-Process Research and Development charge.
• We’ll now examine how Biogen’s earnings beat but reduced full-year guidance reshape its investment narrative and future risk‑reward profile.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Biogen Investment Narrative Recap

To own Biogen today, you generally need to believe that newer neurology and rare disease drugs like LEQEMBI, SKYCLARYS and ZURZUVAE can offset mounting pressure on the older multiple sclerosis portfolio. The Q1 2026 earnings beat and lower full year guidance largely reinforce that trade off rather than change it, with higher R&D and business development spending pulling near term profitability against the key Alzheimer’s ramp catalyst and the ongoing risk of MS erosion and tighter reimbursement.

The felzartamab Greater China deal is the announcement that most clearly ties into this earnings update, because its US$100 million upfront payment will appear as an Acquired In Process R&D charge and adds to the spending that is already weighing on 2026 guidance. At the same time, it fits with Biogen’s effort to broaden beyond MS into immunology and kidney diseases, which could diversify the catalyst set away from a handful of neurology launches over time.

Yet behind the excitement around LEQEMBI and new indications, the growing pressure on Biogen’s older MS drugs and reimbursement terms is something investors should be aware of...

Biogen's narrative projects $9.4 billion revenue and $2.1 billion earnings by 2028. This implies a 2.1% yearly revenue decline but an earnings increase of about $0.6 billion from $1.5 billion today.

Uncover how Biogen's forecasts yield a $205.67 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting Biogen to grow earnings to about US$3.3 billion by 2028, even as MS revenues came under pressure, so this guidance cut and higher R&D bill could prompt you to rethink whether that faster growth path still feels realistic or if the more cautious consensus view on Biogen’s risks and rewards better matches your own comfort level.

Explore 7 other fair value estimates on Biogen - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.